ArticleMovement disorders clinical practice2026
FXTAS and the Spectrum of FMR1 Premutation-Associated Phenotypes in Latin America: A Scoping Review.
Article in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder caused by FMR1 premutation expansions (55-200 CGG repeats). Although well described in populations of predominantly European ancestry, FXTAS remains poorly characterized in Latin America due to limited awareness, restricted access to molecular diagnostics, and scarce epidemiological data.
objectiveTo synthesize available evidence on FXTAS and other FMR1 premutation-associated phenotypes in Latin America, focusing on epidemiology, clinical and neuroimaging features, diagnostic approaches, and atypical presentations.
methodsA scoping review was conducted following PRISMA-ScR guidelines. PubMed, EMBASE, Scopus, and LILACS were searched without date restrictions (last search: April 2025). Eligible studies reported FXTAS cases or FMR1 premutation carriers from Latin American countries. Data were extracted on demographics, clinical manifestations, neuroimaging, molecular findings, and country of origin.
resultsTwenty-five studies including 5531 participants reported 38 FXTAS cases and 386 premutation carriers without FXTAS. Diagnoses of FXTAS occurred mainly between ages 53 and 85 years. Gait ataxia and tremor predominated, while parkinsonism, peripheral neuropathy, executive dysfunction, and psychiatric symptoms were also reported. Generalized cerebral atrophy was more frequent than the middle cerebellar peduncle sign. Atypical phenotypes, including spastic paraparesis and progressive supranuclear palsy-like presentations, contributed to diagnostic delays. Premutation carriers commonly exhibited fragile X-associated primary ovarian insufficiency and neuropsychiatric manifestations.
conclusionsFXTAS is likely underdiagnosed in Latin America despite recognizable clinical patterns and associated premutation-related conditions. Improving clinician awareness, access to genetic testing, and standardized diagnostic evaluation is essential. Prospective regional studies are needed to define prevalence, penetrance, and gene-environment interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.